Oatmeal Healthoatmealhealth.com · public-data estimate, October 2026

Doylestown Health

Lung screening gap across 4 counties in New Jersey and Pennsylvania

130,000to210,000adults in its service area qualify for lung cancer screening and are not being screened

About 2,200 people here are diagnosed with lung cancer each year, and 62% are found at a late stage, when it is hardest to treat.

Explore the screening network
NYMDNJPA
4 counties1 acute care hospitalService area
160,000 to 260,000adults likely qualify under USPSTF 2021 criteria (estimate)
1,300lung cancer deaths a year in these counties, 2020 to 2024
19.9%of eligible adults screened in these states, vs 18.2% nationally

Estimates from public data only; no patient information. Sources and method below.

Where the eligible adults live

The counties where most of Doylestown Health's Medicare inpatients live. Darker areas hold more adults who likely qualify, which is where outreach would start. Hover or tap any area for its estimate.

Adults likely eligible, per neighborhood

0+170+230+280+340+410+500+

Acute care hospital in this system

Counties in the service area

CountyStateAdults likely eligibleLung cancer deaths per 100kMedicare screens billed locally, 2024
Philadelphia CountyPennsylvania80,700 to 117,80035.12,930
Montgomery CountyPennsylvania38,000 to 73,60025.0633
Bucks CountyPennsylvania38,600 to 60,20027.5452
Hunterdon CountyNew Jersey4,700 to 11,20020.3128

Every county in the service area had Medicare lung screening reads billed locally in 2024. County names link to their Missing Millions page.

What closing the gap would mean

If screening in these counties rose from 19.9% to 24.9%, five points above today, about 8,100 to 13,100 more people would be screened each year.

In the National Lung Screening Trial, low-dose CT screening lowered lung cancer deaths by 20% compared with chest X-ray. Today about 62% of lung cancers here are found at a late stage.

Illustrative estimate: eligible adults (range) times the change in screening rate. Not a forecast or a guarantee.

Each year in these counties

2,200new lung cancers
1,400found at a late stage
1,300lung cancer deaths

NCI and CDC State Cancer Profiles, annual averages.

Screening at Doylestown Health today

Public Medicare claims do not attribute lung screening reads to Doylestown Health locations. Radiologists who read for a health system often bill through a separate radiology group, so Doylestown Health's screening volume is best measured from its own records.

Most adults who qualify see a primary care clinician every year. We count 123 primary care clinicians, 4 pulmonologists and 0 thoracic surgeons practicing at Doylestown Health locations. A 20 pack-year smoking history is often missing from structured EHR fields, so many eligible patients are never flagged.

CMS Medicare Physician and Other Practitioners 2024 (CPT 71271); clinicians matched to Doylestown Health by practice address using the AHRQ Compendium of U.S. Health Systems 2023, so reads billed by outside radiology groups are not included. The all-payer estimate scales Medicare fee-for-service by the local Medicare Advantage share (48%, CMS) and, at the high end, by the share of eligible adults under 65 (65%).

1 acute care hospital

  • Doylestown HospitalDoylestown, PA

Find them, reach them, give radiologists a second opinion

LungIQ Find

Reads clinical notes, diagnoses and medications in the EHR and returns a ranked list of patients likely eligible, including those whose pack-year history is missing. Start with a CSV export refreshed every 1, 3 or 6 months, or connect through FHIR or HL7.

LungNAV Reach

An AI patient navigator that texts and calls patients in 70+ languages, answers questions about the scan, and hands each patient to your scheduling team or nurse navigators with a call summary.

LungAI Second opinion

Gives radiologists a malignancy risk score for each nodule, factoring in change since the prior scan, inside the PACS and CADe software they already use. The radiologist makes the final call.

LungAI is an investigational medical device and has not been cleared by FDA. It is not commercially available in the United States.

How we estimate the gap

Modeled estimates from public data. They are not a count of Doylestown Health patients and contain no patient information.

  • Service area: CMS Hospital Service Area File 2025 (counties within 120 miles of a system hospital holding 80% of its Medicare inpatients, plus any county with at least 1%); hospitals from the AHRQ Compendium of U.S. Health Systems, 2023.
  • Eligible adults, low estimate: Oatmeal Health Missing Millions (Census 2025 population, CDC PLACES smoking, USPSTF 2021).
  • Eligible adults, high estimate: University of Minnesota National Lung Cancer Screening Estimates (Haynes 2026), which also counts former smokers.
  • Screening rate: American Lung Association, State of Lung Cancer 2025.
  • Lung cancer cases and deaths: NCI and CDC State Cancer Profiles (incidence 2019 to 2023, deaths 2020 to 2024).
  • Screening volume: CMS Medicare Physician and Other Practitioners, 2024; CMS Medicare Advantage State/County Penetration, September 2026.

LungAI is an investigational medical device and has not been cleared by FDA. Oatmeal Health is preparing a 510(k) premarket notification. LungAI is not commercially available in the United States.

See Doylestown Health's own numbers

In a 30 minute review we replace these public estimates with counts from your own records and agree on what a first program would look like.